The effects of ARID1A mutation in gastric cancer and its significance for treatment-Reference-Cited by-同舟云学术

The effects of ARID1A mutation in gastric cancer and its significance for treatment

Published:2023-11-26 Issue:1 Volume:23 Page:
ISSN:1475-2867
Container-title:Cancer Cell International
language:en
Short-container-title:Cancer Cell Int

Author:

Lu Shan,Duan Ruifeng,Cong Liang,Song Ying

Abstract

AbstractGastric cancer (GC) has emerged as a significant issue in public health all worldwide as a result of its high mortality rate and dismal prognosis. AT-rich interactive domain 1 A (ARID1A) is a vital component of the switch/sucrose-non-fermentable (SWI/SNF) chromatin remodeling complex, and ARID1A mutations occur in various tumors, leading to protein loss and decreased expression; it then affects the tumor biological behavior or prognosis. More significantly, ARID1A mutations will likely be biological markers for immune checkpoint blockade (ICB) treatment and selective targeted therapy. To provide theoretical support for future research on the stratification of individuals with gastric cancer with ARID1A as a biomarker to achieve precision therapy, we have focused on the clinical significance, predictive value, underlying mechanisms, and possible treatment strategies for ARID1A mutations in gastric cancer in this review.

Funder

13th Five-year Science and Technology Project of Jilin Provincial Education Department

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

https://link.springer.com/content/pdf/10.1186/s12935-023-03154-8.pdf

Reference102 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Jones S, Wang TL, Shih IM, et al. Frequent mutations of chromatin remodeling gene ARID1A in Ovarian Clear Cell Carcinoma. Science. 2010;330:228–31.

3. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. New Engl J Med. 2010;363:1532–43.

4. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several Tumor types. Hum Mutat. 2012;33:100–3.

5. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43:1219–23.